Unnamed: 0,title,date,stock,sentiment
838754.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,MNTA,negative
838755.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,MNTA,negative
838756.0,"H.C. Wainwright Reiterates Buy on Momenta Pharmaceuticals, Raises Price Target to $40",2020-05-08 09:28:00-04:00,MNTA,neutral
838757.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,MNTA,negative
838758.0,"Momenta Pharmaceuticals Q1 EPS $(0.340) Beats $(0.480) Estimate, Sales $8.700M Beat $4.330M Estimate",2020-05-07 07:25:00-04:00,MNTA,neutral
838759.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,MNTA,neutral
838760.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,MNTA,positive
838761.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,MNTA,positive
838762.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,MNTA,positive
838763.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,MNTA,negative
838764.0,"Goldman Sachs Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating, Announces $29 Price Target",2020-03-12 05:27:00-04:00,MNTA,neutral
838765.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.,2020-03-02 11:18:00-05:00,MNTA,positive
838766.0,"Cantor Fitzgerald Reiterates Neutral on Momenta Pharmaceuticals, Raises Price Target to $30",2020-02-26 11:27:00-05:00,MNTA,neutral
838767.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,MNTA,negative
838768.0,"Momenta Pharmaceuticals Q4 EPS $(0.85) Misses $(0.56) Estimate, Sales $8.182M Beat $5.56M Estimate",2020-02-26 07:29:00-05:00,MNTA,negative
838769.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,MNTA,negative
838770.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,MNTA,neutral
838771.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,MNTA,negative
838772.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-20 10:26:00-05:00,MNTA,neutral
838773.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,MNTA,negative
838774.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,MNTA,negative
838775.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,MNTA,positive
838776.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,MNTA,neutral
838777.0,Momenta Pharmaceuticals shares are trading higher after Stifel maintained a Buy rating on the stock and raised the price target from $29 to $43.,2020-01-28 10:32:00-05:00,MNTA,positive
838778.0,"Stifel Maintains Buy on Momenta Pharmaceuticals, Raises Price Target to $43",2020-01-28 08:30:00-05:00,MNTA,neutral
838779.0,Momenta Pharmaceuticals shares are trading lower in sympathy with the broader market as anxiety around the coronavirus outbreak in China spreads to global markets. NOTE: Leaders at Davos have doubts a phase 2 U.S.-China deal will be reached before Trump's term.,2020-01-21 11:30:00-05:00,MNTA,neutral
838780.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,MNTA,neutral
838781.0,75 Biggest Movers From Yesterday,2020-01-16 04:37:00-05:00,MNTA,neutral
838782.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,MNTA,neutral
838783.0,36 Stocks Moving In Wednesday's Mid-Day Session,2020-01-15 12:07:00-05:00,MNTA,neutral
838784.0,"Benzinga's Top Upgrades, Downgrades For January 15, 2020",2020-01-15 10:11:00-05:00,MNTA,positive
838785.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,MNTA,negative
838786.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,MNTA,neutral
838787.0,21 Stocks Moving in Wednesday's Pre-Market Session,2020-01-15 07:43:00-05:00,MNTA,neutral
838788.0,Momenta Pharmaceuticals shares are trading higher after JP Morgan analysts upgraded the company's stock from Neutral to Overweight and announced a $30 price target.,2020-01-15 07:09:00-05:00,MNTA,positive
838789.0,"JP Morgan Upgrades Momenta Pharmaceuticals to Overweight, Announces $30 Price Target",2020-01-15 07:00:00-05:00,MNTA,neutral
838790.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,MNTA,neutral
838791.0,48 Stocks Moving In Tuesday's Mid-Day Session,2020-01-14 12:06:00-05:00,MNTA,neutral
838792.0,"Momenta Expects $545.1M In Cash, Cash Equivalents, And Marketable Securities At Year-end 2019; Sees FY20 Non-GAAP Operating Expense $220M-$240M",2020-01-13 07:49:00-05:00,MNTA,positive
838793.0,Momenta Pharma Names Young Kwon CFO,2020-01-03 08:06:00-05:00,MNTA,neutral
838794.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,MNTA,neutral
838795.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,MNTA,negative
838796.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,MNTA,negative
838797.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,MNTA,neutral
838798.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,MNTA,neutral
838799.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,MNTA,positive
838800.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,MNTA,negative
838801.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-18 10:43:00-05:00,MNTA,neutral
838802.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,MNTA,positive
838803.0,Momenta Pharma Prices ~14.5M Common Shares At $15.50/Share,2019-12-12 08:04:00-05:00,MNTA,positive
838804.0,13 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-12 07:37:00-05:00,MNTA,neutral
838805.0,70 Biggest Movers From Yesterday,2019-12-12 06:31:00-05:00,MNTA,neutral
838806.0,50 Stocks Moving In Wednesday's Mid-Day Session,2019-12-11 12:11:00-05:00,MNTA,neutral
838807.0,32 Stocks Moving In Wednesday's Pre-Market Session,2019-12-11 07:48:00-05:00,MNTA,neutral
838808.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,MNTA,negative
838809.0,Momenta Pharma shares are trading lower after the company reported a $200 million common stock offering.,2019-12-10 16:05:00-05:00,MNTA,neutral
838810.0,Momenta Pharma Reports $200M Common Stock Offering,2019-12-10 16:04:00-05:00,MNTA,neutral
838811.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,MNTA,positive
838812.0,Momenta Pharmaceuticals Option Alert: Jan 17 $18 Calls Sweep (33) near the Ask: 800 @ $1.155 vs 0 OI; Ref=$17.92,2019-12-06 12:18:00-05:00,MNTA,positive
838813.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,MNTA,negative
838814.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,MNTA,neutral
838815.0,"Momenta Pharm 8-K Shows Co. Confirmed First Patient In Unity Study Of M281 In Hemolytic Disease Of Fetus, Newborn Delivered Full-Term Baby",2019-11-15 08:11:00-05:00,MNTA,neutral
838816.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,MNTA,neutral
838817.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,MNTA,positive
838818.0,"SunTrust Robinson Humphrey Initiates Coverage On Momenta Pharmaceuticals with Buy Rating, Announces $29 Price Target",2019-11-12 06:30:00-05:00,MNTA,neutral
838819.0,Stocks That Hit 52-Week Highs On Friday,2019-11-08 10:30:00-05:00,MNTA,neutral
838820.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,MNTA,negative
838821.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2019",2019-11-06 09:56:00-05:00,MNTA,positive
838822.0,Wells Fargo Initiates Coverage On Momenta Pharmaceuticals with Outperform Rating,2019-11-06 06:23:00-05:00,MNTA,positive
838823.0,"Momenta Pharmaceuticals Q3 EPS $(0.45) Beats $(0.5) Estimate, Sales $6.39M Beat $5.24M Estimate",2019-10-31 07:51:00-04:00,MNTA,neutral
838824.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,MNTA,neutral
838825.0,Momenta Pharmaceuticals shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $24 per share.,2019-09-25 14:08:00-04:00,MNTA,positive
838826.0,"Benzinga's Top Upgrades, Downgrades For September 25, 2019",2019-09-25 10:04:00-04:00,MNTA,positive
838827.0,"HC Wainwright & Co. Initiates Coverage On Momenta Pharmaceuticals with Buy Rating, Announces $24 Price Target",2019-09-25 07:08:00-04:00,MNTA,neutral
838828.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,MNTA,negative
838829.0,"Momenta Pharmaceuticals Q2 EPS $(1.16) Misses $(0.43) Estimate, Sales $5.182M Miss $9.2M Estimate",2019-08-02 07:09:00-04:00,MNTA,negative
838830.0,"Momenta Pharma Reports Fast Track Designation For M281 In Hemolytic Disease Of The Fetus, Newborn",2019-07-30 07:40:00-04:00,MNTA,neutral
838831.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,MNTA,neutral
838832.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,MNTA,negative
838833.0,Momenta Pharma Reports Settlement Deal With Amphastar Resolving Enoxaparin Sodium Injection Litigation,2019-06-19 08:00:00-04:00,MNTA,positive
838834.0,"Momenta Pharmaceuticals Q1 EPS $(0.46) Misses $(0.43) Estimate, Sales $4.113M Miss $10.12M Estimate",2019-05-02 08:27:00-04:00,MNTA,negative
838835.0,Momenta Pharmaceuticals Announces Presentations At American Association For Cancer Research Annual Meeting 2019,2019-03-28 07:11:00-04:00,MNTA,negative
838836.0,Momenta Pharma Highlights Publication Of New Data Supporting M281 As First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta,2019-03-21 08:46:00-04:00,MNTA,positive
838837.0,"Benzinga's Top Upgrades, Downgrades For March 16, 2019",2019-03-18 08:53:00-04:00,MNTA,positive
838838.0,BTIG Research Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating,2019-03-18 07:14:00-04:00,MNTA,neutral
838839.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,MNTA,neutral
838840.0,"Momenta Pharmaceuticals Q4 EPS $(0.10) Down From $0.18 YoY, Sales $10.8M Miss $17.11M Estimate",2019-02-22 06:38:00-05:00,MNTA,negative
838841.0,"Earnings Scheduled For February 22, 2019",2019-02-22 04:07:00-05:00,MNTA,neutral
838842.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,MNTA,neutral
838843.0,Momenta Pharmaceuticals Stockholders Approved Amendment To Increase Number Of Authorized Shares Of Co.'s Common Stock From 100M To 200M,2019-01-30 17:00:00-05:00,MNTA,positive
838844.0,"Momenta Pharmaceuticals Announces First Subject Dosed In Phase 1/2 Clinical Trial Of M254, Hypersialylated Immunoglobulin G",2019-01-29 08:05:00-05:00,MNTA,neutral
838845.0,41 Stocks Moving In Friday's Mid-Day Session,2019-01-04 12:17:00-05:00,MNTA,neutral
838846.0,48 Biggest Movers From Yesterday,2018-12-12 05:14:00-05:00,MNTA,neutral
838847.0,48 Biggest Movers From Friday,2018-12-10 05:23:00-05:00,MNTA,neutral
838848.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,MNTA,neutral
838849.0,Momenta Pharmaceuticals Prices 17.3M Share Public Offering of Common Stock @$11.50/Share,2018-12-06 21:00:00-05:00,MNTA,positive
838850.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,MNTA,negative
838851.0,"Momenta Pharmaceuticals Says Will Be Able To Commercialize M923 In The US, Pending Regulatory Pathway, As Early As November 20, 2023",2018-12-03 16:06:00-05:00,MNTA,neutral
838852.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,MNTA,negative
838853.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,MNTA,neutral
838854.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,MNTA,negative
838855.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,MNTA,negative
838856.0,"Momenta Pharmaceuticals, Inc. Q3 Adj. EPS $(0.45) Beats $(0.54) Estimate, Sales $14.884M Miss $17.55M Estimate",2018-11-07 06:19:00-05:00,MNTA,negative
838857.0,AbbVie Announces HUMIRA Global Patent License With Momenta,2018-11-06 16:48:00-05:00,MNTA,neutral
838858.0,"PiperJaffray Initiates Coverage On Momenta Pharmaceuticals with Overweight Rating, Announces $35 Price Target",2018-11-05 09:29:00-05:00,MNTA,negative
838859.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,MNTA,neutral
838860.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,MNTA,negative
838861.0,44 Biggest Movers From Yesterday,2018-10-15 05:06:00-04:00,MNTA,neutral
838862.0,41 Stocks Moving In Friday's Mid-Day Session,2018-10-12 13:42:00-04:00,MNTA,neutral
838863.0,44 Biggest Movers From Yesterday,2018-10-12 04:45:00-04:00,MNTA,neutral
838864.0,Momenta Sees Added Captial Raise To Fund Ongoing Programs Over Next 2 Years,2018-10-01 06:05:00-04:00,MNTA,neutral
838865.0,Momenta Sees Restructuring Plan Costing $17M-$20M Through 2018,2018-10-01 06:04:00-04:00,MNTA,neutral
838866.0,"Momenta Pharma Sees Realizing ~$250M In Cost Savings Over 5-Year Plan Related To Restructuring, Elimination Of Programs, 110 Positions",2018-10-01 06:04:00-04:00,MNTA,neutral
838867.0,"Momenta Pharma Approved Plan To Restructure Exec Team, Reduce Workforce By ~50%",2018-10-01 06:03:00-04:00,MNTA,positive
838868.0,"Momenta Pharma Has Initiated Discussions With Its Collaboration Partner, Mylan, To Exit Its Participation In Development Of Its Other 5 Biosimilar Programs Including M834, Intends To Focus Solely On Continued Development Of M710",2018-10-01 06:03:00-04:00,MNTA,neutral
838869.0,Momenta Pharma Sees Filing Biologics License Application For M923 With FDA,2018-10-01 06:02:00-04:00,MNTA,neutral
838870.0,"Momenta Pharma Reports Completion Of Strategic Review, Will 'Prioritize Pipeline of Novel Drug Candidates for Immune-Mediated Diseases and Reduce Investment in Biosimilars by Focusing on Two Later-stage Assets'",2018-10-01 06:01:00-04:00,MNTA,positive
838871.0,Momenta Pharmaceuticals shares are trading 7.4% lower to $26.03 after drastic earnings miss.,2018-08-09 10:19:00-04:00,MNTA,negative
838872.0,Momenta Says FY18 Opex Guidance Is No Longer Accurate Due To Co.'s Ongoing Strategic Review; Co. Plans To Update FY18 Opex Guidance When It Reports Q3 Results,2018-08-09 06:18:00-04:00,MNTA,negative
838873.0,"Momenta Pharmaceuticals Q2 EPS $(0.91) Misses $(0.41) Estimate, Sales $13.031M Miss $21.05M Estimate",2018-08-09 06:09:00-04:00,MNTA,negative
838874.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,MNTA,neutral
838875.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,MNTA,neutral
838876.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,MNTA,neutral
838877.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,MNTA,neutral
838878.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,MNTA,positive
838879.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,MNTA,neutral
838880.0,"Momenta Pharmaceuticals And Human Genome Sciences Have Come To An Understanding Regarding A Prior Contract Dispute; As Part Of The Dispute, Momenta Will Pay Human Genome Sciences $15M By Aug. 15, 2018 And $15M By July 1, 2019",2018-06-28 17:02:00-04:00,MNTA,negative
838881.0,"Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating",2018-06-11 16:54:00-04:00,MNTA,negative
838882.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,MNTA,neutral
838883.0,"Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing",2018-05-23 08:15:00-04:00,MNTA,neutral
838884.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,MNTA,positive
838885.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,MNTA,neutral
838886.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,MNTA,neutral
838887.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,MNTA,neutral
838888.0,"Momenta Sees Continuing To Recognize Sales From Mylan's $45M Upfront Payment On Quarterly Basis, Sees Collab. Reimbursement Sales $0-$2M",2018-05-08 07:21:00-04:00,MNTA,neutral
838889.0,Momenta Sees Q2 Adj. Operating Expense $45M-$55M; FY18 Adj. Opex $180M-$220M,2018-05-08 07:21:00-04:00,MNTA,neutral
838890.0,"Momenta Pharmaceuticals Q1 EPS $(0.63) Misses $(0.48) Estimate, Sales $4.85M Miss $18.45M Estimate",2018-05-08 07:03:00-04:00,MNTA,negative
838891.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,MNTA,neutral
838892.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,MNTA,negative
838893.0,Mylan Inks Deal With Mapi Pharma For Multiple Sclerosis Drug,2018-04-12 11:05:00-04:00,MNTA,neutral
838894.0,Amphastar  Pharmaceuticals Says U.S.  District Court Entered Final Judgement In Favor Of Co. In A Lawsuit Brought By Momenta Pharmaceuticals,2018-03-21 06:02:00-04:00,MNTA,positive
838895.0,"Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot",2018-03-06 10:52:00-05:00,MNTA,positive
838896.0,Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy,2018-02-22 10:33:00-05:00,MNTA,neutral
838897.0,"Benzinga's Top Upgrades, Downgrades For February 22, 2018",2018-02-22 09:57:00-05:00,MNTA,positive
838898.0,Stifel Nicolaus Upgrades Momenta Pharmaceuticals to Buy,2018-02-22 07:41:00-05:00,MNTA,neutral
838899.0,"Momenta Pharma Reports Q4 EPS $0.18 vs $(0.31) Est., Sales $64.61M vs $66.58M Est., May Not Compare",2018-02-21 08:02:00-05:00,MNTA,neutral
838900.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,MNTA,neutral
838901.0,"Momenta Pharmaceuticals Announces FDA Approval, Launch of Glatopa (glatiramer acetate injection) 40 mg/mL",2018-02-13 03:44:00-05:00,MNTA,positive
838902.0,"Momenta Pharmaceuticals Shares Up 7% Following News Compliance Status For Co.'s McPherson, Kansas Facility Was Amended To Voluntary Action Indicated, Suggesting 'potential for the near-term FDA approval of Sandoz's Glatopa 40 mg ANDA'",2018-01-30 12:55:00-05:00,MNTA,positive
838903.0,"Momenta Pharma Reports McPherson, Kansas Facility Compliance Status Amended To VAI, Provides 'the potential for the near-term FDA approval of Sandoz's Glatopa 40 mg ANDA'",2018-01-30 08:03:00-05:00,MNTA,positive
838904.0,"Momenta Trade Resumes, Up 10.2% At $16.75",2018-01-19 12:21:00-05:00,MNTA,neutral
838905.0,"Momenta Pharma Shares Halted On Circuit Breaker, Up 14.52%",2018-01-19 12:15:00-05:00,MNTA,positive
838906.0,Teva's Cost-Cutting Plan Nets A Mizuho Upgrade,2018-01-09 10:56:00-05:00,MNTA,neutral
838907.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,MNTA,neutral
838908.0,40 Biggest Movers From Friday,2018-01-08 05:59:00-05:00,MNTA,neutral
838909.0,30 Stocks Moving In Friday's Mid-Day Session,2018-01-05 12:15:00-05:00,MNTA,neutral
838910.0,"Momenta Pharma Offers Top-Line Phase 1 Data Showing Proof Of Mechanism For M281: Showed Safety, Tolerability With No Adverse Events",2018-01-05 08:05:00-05:00,MNTA,negative
838911.0,9 Stocks Moving In Wednesday's After-Hours Session,2018-01-03 17:12:00-05:00,MNTA,neutral
838912.0,"Momenta and Mylan Announce Development Strategy for M710, Plan To Initiate Pivotal Clinical Trial In 1H18",2018-01-03 16:07:00-05:00,MNTA,neutral
838913.0,23 Stocks Moving In Friday's Pre-Market Session,2017-12-08 08:12:00-05:00,MNTA,neutral
838914.0,"Momenta Pharma Reports Q3 EPS $(0.44) vs $(0.46) Est., Sales $24.1M vs $30.6M Est.",2017-11-01 08:06:00-04:00,MNTA,neutral
838915.0,"Momenta, Mylan On M834 Say, 'Momenta and Mylan continue to gather and analyze these data to inform next steps for the program'",2017-11-01 08:04:00-04:00,MNTA,neutral
838916.0,"Momenta Pharma, Mylan Report Initial Results From Phase 1 Trial For M834: Did Not Meet Primary Endpoints",2017-11-01 08:03:00-04:00,MNTA,neutral
838917.0,20 Biggest Mid-Day Losers For Thursday,2017-10-05 12:52:00-04:00,MNTA,negative
838918.0,"The Market In 5 Minutes: Shopify, Equifax And More",2017-10-05 09:55:00-04:00,MNTA,neutral
838919.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2017",2017-10-05 09:26:00-04:00,MNTA,positive
838920.0,Momenta Pharma Could Face Pressure Following Approval Of Mylan's Generic Copaxone,2017-10-05 08:58:00-04:00,MNTA,positive
838921.0,Stifel Nicolaus Downgrades Momenta Pharmaceuticals to Hold,2017-10-05 06:56:00-04:00,MNTA,neutral
838922.0,Momenta Pharma Shares Were Unaffected Following Late Afternoon Downgrade From Buy To Hold By Stifel,2017-10-04 17:02:00-04:00,MNTA,positive
838923.0,18 Biggest Mid-Day Losers For Wednesday,2017-10-04 12:38:00-04:00,MNTA,negative
838924.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-04 08:07:00-04:00,MNTA,neutral
838925.0,"Momenta Pharma Promotes Ganesh Kaundinya To Roles Of COO, Chief Scientific Officer",2017-10-02 16:10:00-04:00,MNTA,positive
838926.0,"Goldman Sachs Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating, Announces $18.00 Price Target",2017-09-28 07:53:00-04:00,MNTA,neutral
838927.0,"Momenta Pharmaceuticals Reports Q2 EPS $(0.50) vs $(0.50) Est.,Sales $23.57M vs $24.64M Est.",2017-08-02 08:05:00-04:00,MNTA,neutral
838928.0,"UPDATE: Momenta Pharma Issues Release Confirming Earlier Reports Of Court Ruling In Favor Or Amphastar Pharma In Generic Lovenox Patent Case; Co. Says Its Patent Was Infringed, But Found To Be Invalid And Unenforceable",2017-07-21 14:22:00-04:00,MNTA,positive
838929.0,U.S. Jury Clears Amphastar Pharmaceuticals inc In Patent Lawsuit By Momenta Pharmaceuticals Inc,2017-07-21 12:34:00-04:00,MNTA,negative
838932.0,Momenta Pharmaceuticals Names Dr. Santiago Arroyo Chief Medical Officer,2017-06-01 08:13:00-04:00,MNTA,neutral
838933.0,12 Biggest Mid-Day Losers For Monday,2017-05-22 13:01:00-04:00,MNTA,negative
838934.0,"Benzinga's Top Upgrades, Downgrades For May 22, 2017",2017-05-22 09:28:00-04:00,MNTA,positive
838935.0,Barclays Downgrades Momenta Pharmaceuticals to Equal-Weight,2017-05-22 07:18:00-04:00,MNTA,neutral
838936.0,"Momenta Pharmaceuticals Reports Q1 EPS $(0.46) vs $(0.66) Est., Sales $26.6M vs $24.4M Est.",2017-05-02 08:14:00-04:00,MNTA,neutral
838937.0,"8-K from Momenta Pharma Shows US Court of Appeals for First Circuit Reversed District Court's Dismissal, Remanded Suit Brought by Amphastar for Further Proceedings",2017-03-08 07:58:00-05:00,MNTA,neutral
838938.0,"Benzinga's Top Upgrades, Downgrades For February 22, 2017",2017-02-22 09:28:00-05:00,MNTA,positive
838939.0,Leerink Swann Downgrades Momenta Pharmaceuticals to Market Perform,2017-02-22 06:44:00-05:00,MNTA,neutral
838940.0,15 Biggest Mid-Day Losers For Tuesday,2017-02-21 13:04:00-05:00,MNTA,negative
838941.0,Mid-Morning Market Update: Markets Open Higher; Wal-Mart Earnings Beat Views,2017-02-21 09:55:00-05:00,MNTA,neutral
838942.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-02-21 08:58:00-05:00,MNTA,neutral
838943.0,"Momenta Pharmaceuticals Reports Q4 EPS $0.60 Does Not Compare To $(0.24) Est., Revenue $34.19M vs. $29.5M Est.",2017-02-21 07:09:00-05:00,MNTA,neutral
838944.0,Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa Fill/Finish Manufacturer,2017-02-17 18:02:00-05:00,MNTA,negative
838945.0,"Momenta Pharma Reports HSR Clearance for Collab, License Deal with CSL; CSL Will Pay $50M Upfront cash Payment",2017-02-17 08:02:00-05:00,MNTA,negative
838946.0,A District Court's Ruling Against Teva Pharma Opens The Door For Generics,2017-01-31 14:51:00-05:00,MNTA,neutral
838947.0,Mid-Afternoon Market Update: Under Armour Drops On Earnings Miss; Jaguar Animal Health Shares Climb,2017-01-31 14:31:00-05:00,MNTA,positive
838948.0,15 Biggest Mid-Day Gainers For Tuesday,2017-01-31 12:20:00-05:00,MNTA,neutral
838949.0,Mid-Morning Market Update: Markets Open Lower; Mastercard Earnings Beat Views,2017-01-31 09:53:00-05:00,MNTA,negative
838950.0,Momenta Pharma Reports District Court Decision to Invalidate Teva's Patents in COPAXONE 40 mg/ML Litigation,2017-01-31 08:06:00-05:00,MNTA,negative
838951.0,Option Alert: Momenta Feb $18 Call; 3150 @Bid @$0.50; Ref=$15.22,2017-01-17 13:43:00-05:00,MNTA,positive
838952.0,"Momenta Shares Resume, Move Higher, Now Up 10%",2017-01-05 16:30:00-05:00,MNTA,positive
838953.0,Momenta Pharma Shares to Resume Trade at 4:30 p.m. EST,2017-01-05 16:12:00-05:00,MNTA,positive
838954.0,"UPDATE: Momenta Will Receive Upfront License Fee Payment of $50M, Up to $550M in Potential Milestone Payments from CSL",2017-01-05 16:03:00-05:00,MNTA,neutral
838955.0,"Momenta Announces Collaboration, License Deal with CSL for Development of Fc Multimer Programs, Including M230",2017-01-05 16:03:00-05:00,MNTA,neutral
838956.0,Momenta Pharma Shares Halted News Pending,2017-01-05 16:00:00-05:00,MNTA,positive
838957.0,"Momenta Pharmaceuticals, Baxalta Entered into Asset Return and Termination Agreement",2017-01-03 08:07:00-05:00,MNTA,positive
838958.0,Momenta Pharma Shares Sell Off Below $15.20 Level as Hearing Co. Has Lost Patent Challenge Against Bristol-Myers Related to '239 Orencia Patent,2016-12-22 14:08:00-05:00,MNTA,positive
838959.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,MNTA,positive
838960.0,CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup,2016-11-29 09:42:00-05:00,MNTA,positive
838961.0,Momenta Pharmaceuticals Announces Phase 3 M923 Met Primary Endpoint and All Secondary Endpoints,2016-11-29 08:02:00-05:00,MNTA,neutral
838962.0,Benzinga's Top Initiations,2016-11-22 12:04:00-05:00,MNTA,positive
838963.0,"Aegis Capital Initiates Coverage On Momenta Pharmaceuticals, Inc. - Common Stock at Hold, Announces $15.00 Target",2016-11-22 09:04:00-05:00,MNTA,neutral
838964.0,"Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine",2016-11-17 08:01:00-05:00,MNTA,positive
838965.0,Morgan Stanley Cuts Teva's Price Target By 33%,2016-11-16 08:23:00-05:00,MNTA,negative
838966.0,"Momenta Pharmaceuticals Reports Q3 EPS $(0.26) vs. Est. $(0.30), Rev. $29.1M vs. Est. $25.68M",2016-11-02 08:09:00-04:00,MNTA,neutral
838967.0,Momenta and Mylan Initiate Phase 1 Clinical Trial for M834,2016-11-02 08:08:00-04:00,MNTA,neutral
838968.0,Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer,2016-11-02 08:03:00-04:00,MNTA,neutral
838969.0,Goldman Says These 25 Healthcare Stocks Are Immune To The Election,2016-10-24 10:55:00-04:00,MNTA,positive
838970.0,5 Stocks Which Rallied Three Days On Increasing Volume,2016-10-12 09:48:00-04:00,MNTA,neutral
838971.0,A Compelling Risk/Reward Seen In Momenta Pharmaceuticals,2016-10-11 14:01:00-04:00,MNTA,positive
838972.0,8 Biggest Mid-Day Gainers For Tuesday,2016-10-11 12:28:00-04:00,MNTA,neutral
838973.0,Benzinga's Volume Movers,2016-10-11 10:40:00-04:00,MNTA,neutral
838974.0,Mid-Morning Market Update: Markets Open Lower; Alcoa Misses Q3 Views,2016-10-11 10:02:00-04:00,MNTA,negative
838975.0,8 Biggest Price Target Changes For Tuesday,2016-10-11 09:57:00-04:00,MNTA,neutral
838976.0,Benzinga's Top Upgrades,2016-10-11 08:56:00-04:00,MNTA,positive
838977.0,"Barclays Upgrades Momenta Pharmaceuticals, Inc. - Common Stock to Overweight, Raises to $19.00",2016-10-11 07:38:00-04:00,MNTA,negative
838978.0,"8-K from Momenta Pharma Shows Details of Deal with Baxalta: Received Initial Cash Payment of $33M, $7M License Payment, $12M Technical, Development Milestone Payments",2016-09-27 08:50:00-04:00,MNTA,neutral
838979.0,"Momenta Pharma Reports Regained Global Development, Commercialization Rights to M923; Terminates Collaboration Deal with Baxalta",2016-09-27 08:02:00-04:00,MNTA,neutral
838980.0,Watch These 5 Huge Put Purchases In Thursday Trade,2016-09-08 02:49:00-04:00,MNTA,positive
838981.0,15 Biggest Mid-Day Losers For Wednesday,2016-09-07 13:21:00-04:00,MNTA,negative
838982.0,Option Alert: MNTA Sep16 10.0 Puts Sweep: 543 @  ASK  $0.40: 565 traded vs 2723 OI: $11.22 Ref,2016-09-07 09:33:00-04:00,MNTA,positive
838983.0,Benzinga's Top Downgrades,2016-09-07 09:02:00-04:00,MNTA,positive
838984.0,Maxim Group Downgrades Momenta Pharmaceuticals to Sell,2016-09-07 07:24:00-04:00,MNTA,neutral
838985.0,"Traders Attributing Recent Moves Lower in Teva, Momenta to Report Final Decision on Patent '250 Copaxone Showed Claims Invalidated",2016-08-24 15:18:00-04:00,MNTA,negative
838986.0,Momenta Pharma Spikes to High of $12.88 on Volume,2016-08-24 15:14:00-04:00,MNTA,neutral
838987.0,"Momenta Pharmaceuticals Reports Q2 EPS $(0.31) vs. Est. $(0.34), Rev. $26.4M vs. Est. $22.9M",2016-08-04 08:39:00-04:00,MNTA,neutral
838988.0,Momenta Reports Discontinuation of Further Accural of Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer,2016-08-04 07:58:00-04:00,MNTA,negative
838989.0,Momenta Pharmaceuticals Initiates Phase 1 Trial of M281,2016-06-09 08:01:00-04:00,MNTA,neutral
838990.0,"Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'",2016-06-06 13:22:00-04:00,MNTA,neutral
838991.0,"Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals at Neutral, Announces $14.00 PT",2016-06-06 07:23:00-04:00,MNTA,neutral
838992.0,Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at #ASCO16,2016-06-04 10:02:00-04:00,MNTA,negative
838993.0,"Momenta Pharma Reports Q1 EPS $(0.35) vs $(0.32) Est., Sales $19.9M vs $28M Est.",2016-05-03 08:08:00-04:00,MNTA,neutral
838994.0,Stocks Hitting 52-Week Lows,2016-02-29 10:12:00-05:00,MNTA,negative
838995.0,"Momenta Pharma Reports Q4 EPS $(0.43) vs $(0.04) Est., Sales $22.4M vs $30.4M Est.",2016-02-18 08:02:00-05:00,MNTA,neutral
838996.0,Momenta Spikes Higher on Volume,2016-01-08 14:07:00-05:00,MNTA,neutral
838997.0,"Mylan, Momenta Pharma Report Global Collab for Joint Development, Commercialization of Six Biosimilar Products",2016-01-08 08:10:00-05:00,MNTA,neutral
838998.0,Momenta Pharmaceuticals Names Matthew P. Ottmer as COO,2015-12-07 10:30:00-05:00,MNTA,neutral
838999.0,Benzinga's Top Initiations,2015-11-23 09:43:00-05:00,MNTA,positive
839000.0,"Barclays Initiates Coverage on Momenta Pharmaceuticals at Equal-weight, Announces $22.00 PT",2015-11-23 03:33:00-05:00,MNTA,neutral
839001.0,Benzinga's Top Initiations,2015-11-13 09:40:00-05:00,MNTA,positive
839002.0,Momenta Reports Temporary Pause of Patient Enrollment in the Necuparanib Phase 2 Study,2015-11-13 08:02:00-05:00,MNTA,neutral
839003.0,"JP Morgan Initiates Coverage on Momenta Pharmaceuticals at Overweight, Announces $26.00 PT",2015-11-13 06:49:00-05:00,MNTA,neutral
839004.0,Momenta Phama Reports US Court of Appeals Decision to Remand Enoxaparin Case Back to District Court,2015-11-10 15:03:00-05:00,MNTA,neutral
839005.0,"Momenta Pharma Reports Q3 Loss of $0.44/Share vs Loss of $0.12/Share Est., Sales $13.8M vs $29M Est.",2015-11-04 08:02:00-05:00,MNTA,negative
839006.0,"Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You",2015-10-05 15:06:00-04:00,MNTA,positive
839007.0,Baxalta Announces Initiation of M923 Clinical Trial with Momenta,2015-10-05 06:33:00-04:00,MNTA,neutral
839008.0,"Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)",2015-10-05 06:31:00-04:00,MNTA,neutral
839009.0,The Coming Drug-Patent Cliff Is Pushing This Portfolio Up,2015-08-20 14:48:00-04:00,MNTA,neutral
839010.0,Benzinga's Top Downgrades,2015-08-06 09:33:00-04:00,MNTA,positive
839011.0,"Goldman Sachs Downgrades Momenta Pharmaceuticals to Neutral, Maintains $27.00 PT",2015-08-06 07:31:00-04:00,MNTA,neutral
839012.0,"Momenta Pharma Reports Q2 Loss $0.04 May Not Compare, Sales $44.9M",2015-08-04 08:06:00-04:00,MNTA,negative
839013.0,"Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConforMIS, Health Net And More",2015-07-02 12:02:00-04:00,MNTA,positive
839014.0,"UBS Downgrades Momenta Pharmaceuticals to Sell, Raises PT to $17.00",2015-07-02 08:29:00-04:00,MNTA,neutral
839015.0,Momenta Pharmaceuticals Announces CFO Retirement and Succession Plan,2015-06-25 08:45:00-04:00,MNTA,positive
839016.0,"Momenta Pharmaceuticals Reports Launch of Glatopa, the First Substitutable Generic for COPAXONE 20mg, First Commercial Sale Will Trigger $10M Milestone Payment",2015-06-18 17:01:00-04:00,MNTA,neutral
839017.0,Momenta Pharma Reports CAFC Decision TO Invalidate Remanded Teva Pharma Patent In COPAXONE 20 mg Suit,2015-06-18 10:38:00-04:00,MNTA,neutral
839018.0,Stifel Nicolaus Initiates Momenta Pharmaceuticals At Buy,2015-06-04 09:12:00-04:00,MNTA,neutral
839019.0,Benzinga's Top Initiations,2015-06-04 09:06:00-04:00,MNTA,positive
839020.0,"Momenta Pharmaceuticals Reports Oral, Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015",2015-06-04 08:05:00-04:00,MNTA,positive
839021.0,Momenta Pharmaceuticals Announces Oral and Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015,2015-06-04 08:05:00-04:00,MNTA,positive
839022.0,"Stifel Nicolaus Initiates Coverage on Momenta Pharmaceuticals at Buy, Announces $26.00 PT",2015-06-04 06:35:00-04:00,MNTA,neutral
839023.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,MNTA,neutral
839024.0,Momenta Pharmaceuticals to Report New Data From Phase 1 Trial of Necuparanib in Pancreatic Cancer Patients,2015-06-01 08:03:00-04:00,MNTA,negative
839025.0,Momenta Pharmaceuticals Prices 7.25M Share Offering @$19.00/Share,2015-05-20 03:50:00-04:00,MNTA,positive
839026.0,Momenta Pharma. Reports Offering Of 7.25M Shares,2015-05-18 16:00:00-04:00,MNTA,positive
839027.0,Momenta Pharma Reports Data Presentation on M402 at ASCO Meeting,2015-05-18 08:04:00-04:00,MNTA,neutral
839028.0,Stocks Hitting 52-Week Highs,2015-05-11 10:13:00-04:00,MNTA,neutral
839029.0,"Momenta Reports Q1 Loss of $0.04/Share vs Loss of $0.44/Share Est., Sales $8.6M vs $11.73M Est.",2015-05-01 08:11:00-04:00,MNTA,negative
839030.0,8-K from Momenta Pharma Shows Co. Will Sell Up to $75M via ATM Equity Offering,2015-04-21 16:31:00-04:00,MNTA,neutral
839031.0,Momenta Pharmaceuticals To Present Data on Glatopa (glatiramer acetate injection) at the American Academy of Neurology's 2015 Annual Meeting,2015-04-17 08:01:00-04:00,MNTA,neutral
839032.0,Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone,2015-04-16 14:54:00-04:00,MNTA,neutral
839033.0,Hearing Momenta Has Requested Expedited Court Decision Related to Copaxone,2015-04-16 13:43:00-04:00,MNTA,neutral
839034.0,UPDATE: Momenta Eligible For Milestone Payments Of Potentially $140M,2015-04-16 12:34:00-04:00,MNTA,neutral
839035.0,"Momenta Pharma Announces FDA Approval Of ANDA For Glatopa, First Substitute Generic For Copaxone",2015-04-16 12:32:00-04:00,MNTA,positive
839036.0,Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa,2015-04-16 12:32:00-04:00,MNTA,positive
839037.0,Mylan Shares Spike Higher on Teva News,2015-04-16 12:31:00-04:00,MNTA,positive
839038.0,"FDA Denies Teva Petition TO Block Generic Copaxone, Momenta Moving Higher On News",2015-04-16 12:29:00-04:00,MNTA,negative
839039.0,Momenta Shares Spike Higher,2015-04-16 12:24:00-04:00,MNTA,positive
839040.0,"Benzinga's M&A Chatter for Tuesday March 31, 2015",2015-03-31 19:59:00-04:00,MNTA,neutral
839041.0,Teva Declines Comment on Earlier Report of Potential Takeover Talks With Momenta,2015-03-31 15:24:00-04:00,MNTA,neutral
839042.0,"Hearing The Deal Says Momenta Takeover Target for Actavis, Teva",2015-03-31 09:53:00-04:00,MNTA,neutral
839043.0,Momenta Pharmaceuticals Announces Preclinal Studies Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS,2015-03-02 15:36:00-05:00,MNTA,positive
839044.0,"Baxter International Notified Momenta that it was Terminating in Part the Development, License and Option Agreement dated December 22, 2011 between Momenta and Baxter -8K",2015-02-17 08:44:00-05:00,MNTA,positive
839045.0,"Momenta Pharma Reports Q4 EPS Loss $0.31 Vs Est Loss $0.26, Sales $16M Vs Est $23.80M",2015-02-17 08:02:00-05:00,MNTA,negative
839046.0,"Earnings Scheduled For February 17, 2015",2015-02-17 04:46:00-05:00,MNTA,neutral
839047.0,Momenta Pharmaceuticals: Is Overdependence On Enoxaparin A Cause For Concern?,2015-02-04 14:00:00-05:00,MNTA,neutral
839048.0,Maxim Group Downgrades Momenta Pharmaceuticals to Sell,2015-01-23 09:14:00-05:00,MNTA,neutral
839049.0,Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC,2015-01-21 08:33:00-05:00,MNTA,positive
839050.0,Supreme Court Sends MS Drug Patent Case Back to Lower Court in Win for Teva,2015-01-20 10:08:00-05:00,MNTA,positive
839051.0,"Option Alert: Momenta Mar $16 Call; 1,871 Contract Trade at Ask @$0.60; Currently $12.16",2015-01-13 14:21:00-05:00,MNTA,positive
839052.0,Notable Option Activity For January 7,2015-01-07 15:57:00-05:00,MNTA,neutral
839053.0,"Option Alert: Momenta Jan $13 Call; 1,931 Contract Trade Above Ask @$0.43; Currently $12.72",2015-01-07 11:20:00-05:00,MNTA,positive
839054.0,Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer,2014-12-01 08:16:00-05:00,MNTA,negative
839055.0,"Momenta Pharma Reports Acceptance of Clinical Trial App in Europe for M923, Co. Will Receive Payment in Dec. '14",2014-12-01 08:09:00-05:00,MNTA,positive
839056.0,"Momenta Pharmaceuticals Announces Acceptance Of A Clinical Trial Application In Europe for M923, A Biosimilar Version Of Humira",2014-12-01 08:00:00-05:00,MNTA,positive
839057.0,"Momenta Pharmaceuticals, Inc. Reports Q3 EPS of $(0.56) vs $(0.43) Est; Revenue of $9.30M vs $13.03M Est",2014-11-05 08:11:00-05:00,MNTA,neutral
839058.0,Momenta Spikes Lower,2014-10-22 14:46:00-04:00,MNTA,negative
839059.0,Stocks Hitting 52-Week Lows,2014-10-13 10:07:00-04:00,MNTA,negative
839060.0,Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial Of Necuparanib In Patients With Pancreatic Cancer,2014-10-09 16:16:00-04:00,MNTA,negative
839061.0,Momenta Pharmaceuticals Exercises Option To Acquire Novel Antibody Program From AnaptysBio,2014-09-08 08:30:00-04:00,MNTA,positive
839062.0,Mylan Release Confirms ANDA for Three-Times-Per-Week Generic Copaxone Accepted,2014-08-28 11:22:00-04:00,MNTA,positive
839063.0,Momenta Pharma Announces ANDA for Three-Times-A-Week Generic Copaxone Accepted,2014-08-28 09:26:00-04:00,MNTA,positive
839064.0,"Momenta Pharmaceuticals, Inc. Reports Q2 EPS of $(0.51) vs $(0.46) Est; Revenue of $11.0M vs $11.22M Est",2014-07-31 08:14:00-04:00,MNTA,neutral
839065.0,Momenta Receives Orphan Designation for Necuparanib in Pancreatic Cancer,2014-06-05 08:03:00-04:00,MNTA,negative
839066.0,"Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals, Inc. at Buy, Announces $19.00 PT",2014-06-02 06:34:00-04:00,MNTA,neutral
839067.0,Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss,2014-05-15 16:41:00-04:00,MNTA,negative
839068.0,"Maxim Group Initiates Coverage on Momenta Pharmaceuticals, Inc. at Buy, Announces $24.00 PT",2014-05-09 08:16:00-04:00,MNTA,neutral
839069.0,"Earlier Bank of America Upgraded Momenta Pharmaceuticals, Inc. to Buy ",2014-05-07 11:11:00-04:00,MNTA,neutral
839070.0,"Form 8-K from Momenta Pharma Shows Co. Entered ATM Equity Sales Deal, May Sell Up to $75M",2014-05-06 08:24:00-04:00,MNTA,neutral
839071.0,"Momenta Pharmaceuticals, Inc. Reports Q1 EPS of $(0.53) vs $(0.55) Est; Revenue of $10.80M vs $8.41M Est",2014-05-06 08:03:00-04:00,MNTA,neutral
839072.0,Momenta Pharma to Present Data Supporting Sialylation Platform,2014-05-02 08:48:00-04:00,MNTA,positive
839073.0,Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit,2014-04-21 10:27:00-04:00,MNTA,positive
839074.0,Morning Market Movers ,2014-04-21 09:47:00-04:00,MNTA,neutral
839075.0,Benzinga's Top #PreMarket Gainers,2014-04-21 08:08:00-04:00,MNTA,positive
839076.0,Amended 13G Filing from SAC Capital on Momenta Pharma Shows Reduced Stake from 3.89% as of Mar. 11th to 4.6%,2014-04-04 16:12:00-04:00,MNTA,neutral
839077.0,Stocks Hitting 52-Week Lows,2014-04-03 10:32:00-04:00,MNTA,negative
839078.0,Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy,2014-03-31 16:37:00-04:00,MNTA,positive
839079.0,Mid-Afternoon Market Update: American Capital Rises as MannKind Shares Take a Hit,2014-03-31 16:03:00-04:00,MNTA,positive
839080.0,13G Filing from SAC Capital on Momenta Pharma Shows 5.6% Stake,2014-03-12 16:07:00-04:00,MNTA,neutral
839081.0,"Momenta Pharmaceuticals, Inc. Reports Q4 EPS of $(0.59) vs $(0.45) Est; Revenue of $12.80M vs $8.53M Est",2014-02-10 08:06:00-05:00,MNTA,neutral
839082.0,UPDATE: Bernstein Research Reiterates on Momenta Pharmaceuticals Following 3Q13 Results Report,2013-11-06 09:23:00-05:00,MNTA,neutral
839083.0,"Momenta Pharmaceuticals, Inc. Reports Q3 EPS of $(0.50) vs $(0.48) Est",2013-11-05 08:09:00-05:00,MNTA,neutral
839084.0,"Momenta Pharmaceuticals, Inc. Reports Q2 EPS of $(0.57) vs $(0.46) Est; Revenue of $4.40M vs $8.40M Est",2013-08-01 08:05:00-04:00,MNTA,neutral
839085.0,Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level,2013-07-26 15:05:00-04:00,MNTA,positive
839086.0,"Canaccord Genuity Upgrades Momenta Pharmaceuticals, Inc. to Buy, Raises PT to $22.00",2013-07-26 13:52:00-04:00,MNTA,neutral
839087.0,Momenta Pharmaceuticals Announces Potential for 2014 Market Entry of Generic Copaxone(R) ,2013-07-26 13:19:00-04:00,MNTA,neutral
839088.0,UPDATE: CAFC Issues Statement on Appeal Win by Momenta in Teva Case,2013-07-26 11:20:00-04:00,MNTA,positive
839089.0,Hearing Momenta Wins Appeal Against Teva,2013-07-26 11:15:00-04:00,MNTA,positive
839090.0,Momenta Pharmaceuticals Spikes Higher,2013-07-26 11:13:00-04:00,MNTA,neutral
839091.0,Momenta Pharma Announces US Patent Issuance for Sialylation Technology,2013-06-25 08:33:00-04:00,MNTA,neutral
839092.0,"Wallachbeth Initiates Coverage on Momenta Pharmaceuticals, Inc. at Buy, Announces $17.00 PT",2013-06-18 07:58:00-04:00,MNTA,neutral
839093.0,"UBS Upgrades Momenta Pharmaceuticals, Inc. to Buy, Raises PT to $17.00",2013-06-06 10:31:00-04:00,MNTA,neutral
839094.0,"UBS Upgrades Momenta Pharmaceuticals, Inc. to Buy",2013-06-06 07:55:00-04:00,MNTA,neutral
839095.0,"Momenta Pharmaceuticals, Inc. Reports Q1 EPS of $(0.48) vs $(0.44) Est; Revenue of $7.60M vs $9.69M Est",2013-04-30 08:00:00-04:00,MNTA,neutral
839096.0,UPDATE: Bank of America Downgrades Momenta Pharmaceuticals to Underperform on Valuation,2013-03-19 07:21:00-04:00,MNTA,neutral
839097.0,"Bank of America Downgrades Momenta Pharmaceuticals, Inc. to Underperform, Maintains $14.00 PO",2013-03-19 06:09:00-04:00,MNTA,negative
839098.0,"Momenta Pharmaceuticals, Inc. Reports Q4 EPS of $(0.35) vs $(0.41) Est; Revenue of $12.70M vs $10.41M Est",2013-02-15 08:08:00-05:00,MNTA,neutral
839099.0,"Earnings Scheduled For February 15, 2013",2013-02-15 04:21:00-05:00,MNTA,neutral
839100.0,Momenta Moves Higher on Report from European Medicines Agency,2013-01-31 13:32:00-05:00,MNTA,neutral
839101.0,Stocks Hitting 52-Week Lows,2012-11-28 10:14:00-05:00,MNTA,negative
839102.0,"Momenta Confirms Appeals Court Denied Petition, Co. to File for Rehearing at Supreme Court Level",2012-11-20 12:43:00-05:00,MNTA,positive
839103.0,Momenta Shares Bouncing Off Lows; Cos. Lovenox Case Loss in Appeals Court Will Stand,2012-11-20 11:47:00-05:00,MNTA,negative
839104.0,Momenta Phamaceuticals Reports Q3 EPS $-0.51 vs $-0.27 Est,2012-11-07 08:08:00-05:00,MNTA,neutral
839105.0,"UBS Maintains Momenta Phamaceuticals at Neutral, Lowers PT from $15 to $14",2012-08-06 12:21:00-04:00,MNTA,negative
839106.0,Hearing Appeals Court Vacates and Remands District Court Ruling in Momenta vs Amphastar Case,2012-08-03 11:28:00-04:00,MNTA,neutral
839107.0,Momenta Decision In Lovenox Case Vacated By U.S. Appeals Court,2012-08-03 11:26:00-04:00,MNTA,neutral
839108.0,Momenta Phamaceuticals Reports Q2 EPS $-0.20 vs $-0.18 Est; Revenues $21.9M vs $18.99M Est,2012-08-02 08:52:00-04:00,MNTA,neutral
839109.0,"UBS Downgrades Momenta Phamaceuticals from Buy to Neutral, Maintains PT at $15",2012-07-20 11:49:00-04:00,MNTA,neutral
839110.0,"UBS Maintains Momenta Phamaceuticals at Buy, Lowers PT from $18 to $15",2012-06-26 10:31:00-04:00,MNTA,negative
839111.0,"Teva Beats Momenta, Mylan in Copaxone Case",2012-06-25 16:43:00-04:00,MNTA,neutral
839112.0,"Social Media Outlook for Monday June 25 (TEVA, MNTA, BMY, XOM)",2012-06-25 11:25:00-04:00,MNTA,neutral
839113.0,Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling ,2012-06-25 10:09:00-04:00,MNTA,negative
839114.0,"Option Alert: Momenta Pharmaceuticals July 19 Call; Block Trade: 4,668 Contracts; Currently $13.95",2012-06-25 10:04:00-04:00,MNTA,negative
839115.0,Morning Market Losers,2012-06-25 09:53:00-04:00,MNTA,negative
839116.0,UPDATE: Canaccord Genuity Downgrades Momenta Pharmaceuticals to Hold on Negative Copaxone Ruling  ,2012-06-25 09:18:00-04:00,MNTA,negative
839117.0,Benzinga's Top Pre-Market Losers,2012-06-25 08:18:00-04:00,MNTA,negative
839118.0,Momenta Pharmaceuticals Falls 20% Pre-Market after Losing Patent Dispute with Teva,2012-06-25 08:14:00-04:00,MNTA,negative
839119.0,From Earlier: Momenta Pharmaceuticals Announces Decision in Teva Patent Litigation  ,2012-06-25 07:27:00-04:00,MNTA,negative
839120.0,"Canaccord Downgrades Momenta Phamaceuticals from Buy to Hold, Lowers PT from $17 to $12",2012-06-25 06:55:00-04:00,MNTA,negative
839121.0,"Canaccord Downgrades Momenta Phamaceuticals from Buy to Hold, Lowers PT from $17 to $12",2012-06-25 05:55:00-04:00,MNTA,negative
839122.0,5 Healthcare Stocks With The Highest Operating Margin,2012-06-18 07:25:00-04:00,MNTA,neutral
839123.0,"Option Alert: Momenta Pharmaceuticals July 17 Call; Block Trade: 2,704 Contracts; Currently $14.75",2012-06-14 13:41:00-04:00,MNTA,negative
839124.0,"Option Alert: Momenta Pharmaceuticals July 19 Call; Block Trade: 5,000 Contracts; Currently $14.58",2012-06-06 11:54:00-04:00,MNTA,negative
839125.0,Momenta Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Oncology Drug Candidate M402,2012-06-04 09:04:00-04:00,MNTA,positive
839126.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash,2012-06-04 03:39:00-04:00,MNTA,positive
839127.0,Momenta Phamaceuticals Reports Q1 EPS $-0.10 May Not Compare vs $0.21 Est; Revenues $24.2M vs $40.51M Est,2012-05-03 08:27:00-04:00,MNTA,neutral
839128.0,Notable Options Activity in Momenta Pharmaceuticals Inc,2012-04-19 12:59:00-04:00,MNTA,neutral
839129.0,"Option Alert: Momenta Pharmaceutical May 19 Call; Block Trade, 2,000 Contracts",2012-04-19 11:23:00-04:00,MNTA,negative
839130.0,"Option Alert: Momenta Pharmaceuticals May 19 Call; Block Trade, 4,577 Contracts",2012-04-18 15:35:00-04:00,MNTA,negative
839131.0,"UBS Maintains Momenta Phamaceuticals at Buy, Lowers PT from $19.5 to $18",2012-04-10 11:44:00-04:00,MNTA,negative
839132.0,Momenta Phamaceuticals Reports Q4 EPS $(0.02) vs $0.27 Est; Revenues $26.10M vs $38.59M Est		 ,2012-02-09 08:31:00-05:00,MNTA,neutral
839133.0,S&P Indices Announces Change to US Index,2012-01-28 17:19:00-05:00,MNTA,neutral
839134.0,Momenta Phamaceuticals Trading 3% Higher on Heavy Volume; Currently at $15.58,2012-01-27 09:35:00-05:00,MNTA,neutral
839135.0,UPDATE: Momenta Pharmaceuticals Motion for Preliminary Injunction Against Amphastar Pharmaceuticals & Watson Pharmaceuticals,2012-01-26 13:15:00-05:00,MNTA,neutral
839136.0,Hearing UBS Says Buy Momenta Now,2012-01-26 11:03:00-05:00,MNTA,neutral
839137.0,Momenta Seeking to Block Amphastar's Generic Lovenox,2012-01-26 09:53:00-05:00,MNTA,negative
839138.0,"Benzinga's Top ETF Gainers, January 5th (AGA, SOXL, FAS, XBI)",2012-01-05 18:19:00-05:00,MNTA,positive
839139.0,Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar),2012-01-02 20:38:00-05:00,MNTA,positive
839140.0,Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics; Baxter to Make Upfront Cash Payment of $33M    ,2011-12-22 16:15:00-05:00,MNTA,neutral
839141.0,"Benzinga's M&A Chatter for Thursday December 15, 2011",2011-12-15 17:47:00-05:00,MNTA,neutral
839142.0,Momenta Pharmaceuticals Acquires Assets From Virdante Pharmaceuticals,2011-12-05 08:01:00-05:00,MNTA,positive
839143.0,"Bank of America Merrill Lynch Maintains Momenta Pharmaceuticals Neutral, PO To $16",2011-11-08 08:19:00-05:00,MNTA,negative
839144.0,Bank of America Raises PO on Momenta Pharmaceuticals to $16,2011-11-08 07:26:00-05:00,MNTA,negative
839145.0,Momenta Pharmaceuticals Reports Q3 EPS $1.18 vs $1.30 Est; Revenues $87.9M vs $90.92M Est	,2011-11-07 08:52:00-05:00,MNTA,neutral
839146.0,"Monday's NASDAQ Winners: Sify Technologies, Rediff.com, Momenta Pharmaceuticals, China Valves Technology",2011-11-01 13:31:00-04:00,MNTA,positive
839147.0,"End-of-Day Market Summary for October 31, 2011",2011-10-31 16:16:00-04:00,MNTA,neutral
839148.0,Top Movers; Sify Technologies up 30%,2011-10-31 15:58:00-04:00,MNTA,positive
839149.0,Momenta Pharmaceuticals Rises 20% After-Hours on Injunction News,2011-10-28 17:11:00-04:00,MNTA,neutral
839150.0,"Momenta Pharmaceuticals Obtains Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. ",2011-10-28 17:00:00-04:00,MNTA,neutral
839151.0,Momenta Pharmaceuticals Announces That Launch of Authorized Generic Lovenox Triggers Change in Collaboration Terms,2011-10-24 17:13:00-04:00,MNTA,neutral
839152.0,Watson Pharmaceuticals Provides Update on District Court Order Concerning Generic Version of LOVENOX,2011-10-09 18:15:00-04:00,MNTA,neutral
839153.0,"Momenta Pharmaceuticals Files for Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. ",2011-09-30 16:10:00-04:00,MNTA,neutral
839154.0,"UBS Upgrades Momenta Pharmaceuticals, Trims PT",2011-09-23 13:12:00-04:00,MNTA,neutral
839155.0,Hearing UBS Upgrades Momenta Pharmaceuticals from Neutral to Buy with $16PT,2011-09-22 13:30:00-04:00,MNTA,neutral
839156.0,Momenta Pharma Sues International Medical Systems; Sues Watson for Patent Infringement; Cites Methods of Producing Enoxaparin Sodium; Sues Amphastar for Patent Infringement,2011-09-21 17:25:00-04:00,MNTA,negative
839157.0,UPDATE: Goldman Sachs Lowers Price Target on Momenta Pharmaceuticals to $12,2011-09-20 09:13:00-04:00,MNTA,negative
839158.0,"Financial Breakfast: Morning News Summary for September 20, 2011",2011-09-20 07:50:00-04:00,MNTA,neutral
839159.0,Benzinga's Top Upgrades,2011-09-20 07:29:00-04:00,MNTA,positive
839160.0,Goldman Sachs Lowers PT on Momenta Pharmaceuticals to $12,2011-09-20 07:01:00-04:00,MNTA,negative
839161.0,"Bank of America Upgrades Momenta Pharmaceuticals to Neutral, Lowers PO to $15",2011-09-20 06:46:00-04:00,MNTA,negative
839162.0,Midday Losers; Momenta Pharmaceuticals Down -23.32%,2011-09-19 12:39:00-04:00,MNTA,negative
839163.0,FDA Approves Amphastar's Generic Lovenox;  Momenta Spiking Lower on News ,2011-09-19 11:22:00-04:00,MNTA,positive
839164.0,Momenta Pharmaceuticals Spiking Lower on Heavy Volume,2011-09-19 11:15:00-04:00,MNTA,negative
839165.0,Notable Put Options Activity in Momenta Pharmaceuticals,2011-08-24 14:56:00-04:00,MNTA,neutral
839166.0,Notable Call Options Activity in Momenta Pharmaceuticals,2011-08-19 13:30:00-04:00,MNTA,neutral
839167.0,Momenta Pharmaceuticals Reports Q2 EPS $1.26 vs $1.13 Est; Revenues $87.5M vs $79.29M Est,2011-08-04 08:10:00-04:00,MNTA,neutral
839168.0,Oppenheimer Has Positive Stance On Momenta Pharmaceuticals,2011-07-11 07:50:00-04:00,MNTA,positive
839169.0,UPDATE: Bank of America Merrill Lynch Initiates Momenta Pharmaceuticals at Underperform,2011-06-28 08:44:00-04:00,MNTA,neutral
839170.0,"Bank of America Initiates Momenta Pharmaceuticals At Underperform, $19 PO",2011-06-28 07:25:00-04:00,MNTA,negative
839171.0,Momenta Pharmaceuticals Study Showing M402 Inhibits Tumor Metastasis in Multiple Murine Oncology Models Published in PLoS One  ,2011-06-20 15:16:00-04:00,MNTA,negative
839172.0,"Wedbush Reiterates PT, Rating On MNTA",2011-06-20 07:43:00-04:00,MNTA,neutral
839173.0,Options Brief: Momenta Pharmaceuticals,2011-06-09 10:00:00-04:00,MNTA,neutral
839174.0,Puts Purchased on Momenta Pharmaceuticals (MNTA),2011-05-10 11:07:00-04:00,MNTA,neutral
839175.0,Momenta Pharma Reports EPS of $1.13 vs. $0.91 Estimate; Revenues $78.2M vs. $67.12M Estimate (MNTA),2011-05-05 08:13:00-04:00,MNTA,neutral
839176.0,Long MNTA and CPWR,2011-02-28 11:48:00-05:00,MNTA,neutral
839177.0,"PRE-MARKET MOVERS:(MCRL),(MNTA),(CYAN),(RVSN)",2011-02-16 09:06:00-05:00,MNTA,neutral
839178.0,Options Brief: Momenta Pharmaceuticals (MNTA),2011-02-15 11:03:00-05:00,MNTA,neutral
839179.0,Momenta Pharma Awarded U.S. Patent For Glatiramer Acetate Methods (MNTA),2011-02-08 16:09:00-05:00,MNTA,positive
839180.0,"Momenta Pharmaceuticals Falls 16% (MNTA, TEVA)",2011-01-25 12:24:00-05:00,MNTA,neutral
839181.0,Timers Market  01-24-2011,2011-01-24 18:40:00-05:00,MNTA,neutral
839182.0,4 Drug Stocks Poised to Stage Comeback,2011-01-20 07:00:00-05:00,MNTA,positive
839183.0,"Wednesday's Put/Call Ratio Leaders (CVBF, MNTA, JDSU, NG, BSX)",2010-12-22 12:48:00-05:00,MNTA,neutral
839184.0,Options Brief: Momenta Pharmaceuticals (MNTA),2010-12-22 10:17:00-05:00,MNTA,neutral
839185.0,"Tuesday's Put/Call Ratio Leaders (ACL, NRG, MNTA, NOG, GRMN)",2010-12-21 12:56:00-05:00,MNTA,neutral
839186.0,Puts Purchased on Momenta Pharmaceuticals (MNTA),2010-12-20 11:06:00-05:00,MNTA,neutral
839187.0,Goldman Sachs Initiates Neutral Rating on Momenta Pharmaceuticals (MNTA),2010-12-20 09:12:00-05:00,MNTA,neutral
839188.0,"Goldman Sachs Initiates MNTA Coverage With A Neutral Rating, $15 PT",2010-12-20 06:37:00-05:00,MNTA,neutral
839189.0,Good Data on Teva's Laquinimod - Analyst Blog,2010-12-15 17:03:00-05:00,MNTA,positive
839190.0,Good Data on Teva's Laquinimod - Analyst Blog,2010-12-15 16:42:00-05:00,MNTA,positive
839191.0,Options Brief: Momenta Pharmaceuticals (MNTA),2010-12-09 12:48:00-05:00,MNTA,neutral
839192.0,"Benzinga's Top Pre-Market NASDAQ Losers (MNTA, NFLX, ASML, ERIC)",2010-12-08 08:29:00-05:00,MNTA,negative
839193.0,"Tuesday's Put/Call Ratio Leaders (CADX, ROC, LH, MNTA, NVS)",2010-11-16 13:10:00-05:00,MNTA,neutral
839194.0,"Benzinga's Top Pre-Market NASDAQ Gainers (NLST, NFLX, EBAY, MNTA)",2010-10-21 08:26:00-04:00,MNTA,positive
839195.0,"Tuesday's Put/Call Ratio Leaders (SNI, VIA.B, OCR, DLR, MNTA)",2010-10-12 13:46:00-04:00,MNTA,neutral
839196.0,"Mad Money Lightning Round OT: Cramer Can't Recommend SandRidge Energy (SD) (MNTA, FTR, CTL, WIN, SD) ",2010-09-15 19:58:00-04:00,MNTA,negative
839197.0,Wedbush Securities Sees Almost 100% Upside In Momenta Pharmaceuticals (MNTA),2010-09-07 18:19:00-04:00,MNTA,positive
839198.0,"Momenta Loses Generic Copaxon Bid (MNTA, TEVA, BIIB)",2010-09-07 11:20:00-04:00,MNTA,negative
839199.0,SNY Seeks to Expand Vaccine Label - Analyst Blog,2010-08-30 08:34:00-04:00,MNTA,positive
839200.0,"Benzingas Volume Movers (MNTA, HAIN, BRLI, PAAS)",2010-08-26 13:29:00-04:00,MNTA,neutral
839201.0,Unconfirmed chatter that (TEVA)will acquire Momenta Pharmaceuticals Inc. (MNTA) at $25.00 a share,2010-08-26 10:40:00-04:00,MNTA,positive
839202.0,"Benzingas Top Pre-Market NASDAQ Gainers (MNTA, SOLF, NFLX, ARNA)",2010-08-26 08:41:00-04:00,MNTA,positive
839203.0,Momenta Pharmaceuticals Up Nearly 5% (MNTA),2010-08-02 15:34:00-04:00,MNTA,neutral
839204.0,Momenta Pharmaceuticals Narrows Loss (MNTA),2010-08-02 08:37:00-04:00,MNTA,negative
839205.0,Momenta Pharmaceuticals Falling On Heavy Volume (NASDAQ:MNTA),2010-07-27 12:01:00-04:00,MNTA,negative
839206.0,"Benzingas Top Pre-Market NASDAQ Losers (MNTA, WERN, NVDA, ARMH)",2010-07-27 08:45:00-04:00,MNTA,negative
839207.0,"Benzingas Volume Movers (MNTA, ONXX, IDSA, GENZ)",2010-07-26 13:27:00-04:00,MNTA,neutral
839208.0,"Momenta Pharmaceuticals Resumes Trading, Skyrocketing (MNTA)",2010-07-23 11:56:00-04:00,MNTA,neutral
839209.0,Momenta Pharma Doubles on Lovenox News (MNTA),2010-07-23 11:51:00-04:00,MNTA,neutral
839210.0,"Pharma Names Rallying on FDA Decision about Lovenox (INSM, MNTA, ABC, MHS)",2010-07-23 11:17:00-04:00,MNTA,neutral
839211.0,FDA Approves Momenta Pharmaceuticals Drug,2010-07-23 11:00:00-04:00,MNTA,positive
839212.0,Momenta Pharma Trading Halted (MNTA),2010-07-23 10:51:00-04:00,MNTA,neutral
839213.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,MNTA,positive
839214.0,Top Narrow Based Indexes Today ,2010-01-22 18:08:00-05:00,MNTA,positive
839215.0,"Benzingas Volume Movers (MNTA, ISRG, TRGL, IPGP, JCOM)",2010-01-22 14:53:00-05:00,MNTA,neutral
839216.0,Teva Pharma (TEVA) moves to expand scope of suit for use of its generic version,2009-11-10 10:30:00-05:00,MNTA,positive
